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Sentinel lymph node (SLN) biopsy has become
standard care for lymph node staging in breast can-
cer, represents a substantial step in the evolution of
breast cancer surgery toward greater conservatism,
and is one of the great success stories in contempo-
rary surgical oncology. The most salient surgical
questions (feasibility, accuracy, case selection, tech-
nique, and morbidity) have been asked and answered,
and it is increasingly diﬃcult to generate debate on
any of them. In contrast, most aspects of SLN
pathology remain controversial and elude consensus.
Is intraoperative assessment worthwhile? Which
method (frozen section, touch prep or smear) is best?
How should SLN be processed for permanent
pathology [single-section hematoxylin and eosin
(H&E) and/or serial sections and/or immunohisto-
chemistry (IHC)]? What is the prognostic signiﬁcance
of SLN micrometastases, especially those detected
only by IHC, or as pN0i+ disease (£0.2 mm in size)?
Is completion axillary dissection (ALND) required
for all patients with SLN who are positive on ﬁnal
pathology? Is there a low-risk group for whom
ALND is unnecessary and can we reliably identify
this group? All of these issues are highly interrelated,
but the last remains the most perplexing for surgeons
and is the subject of a substantial literature. What
have we learned?
PREDICTING METASTASIS TO NON-SLN
Non-SLN metastases are present in 40–50% of
SLN-positive patients1,2 and are predicted by the
same variables which predict metastasis to the SLN
(or to axillary nodes in general): the most important
are tumor size and lymphovascular invasion (LVI).
Non-SLN metastases are also predicted by the char-
acteristics of the SLN metastasis: the most important
are method of detection (frozen section, H&E, serial
sections, or IHC), size of SLN metastasis [<0.2 mm
(pN0i+), 0.2–2 mm (pN1mi),>2 mm (pN1)], number
of positive SLN, presence of extranodal invasion, and
number of negative SLN removed. Many papers pre-
dict non-SLN metastases on the basis of one or more
variables, as previously summarized by Van Zee (20
studies in 26–702 patients).3 A meta-analysis by
Degnim et al.4 (11 studies in 60–389 patients) found
that non-SLN metastasis was most strongly associ-
ated with tumor size, LVI, more than one positive
SLN, SLN metastasis >2 mm, and extranodal
extension. A meta-analysis by Cserni et al.5 (25
studies) found that non-SLN metastases were present
in 20% of patients with low-volume SLN disease and
in 9% with SLN metastases detected only by IHC.
Finally, a large series by Viale et al.6 of 1,228 SLN-
positive patients found that the risk of non-SLN
metastasis in patients with the most favorable com-
bination of predictive factors was no less than 13%.
THE MSKCC NOMOGRAM
The prediction of non-SLN status on the basis
of one or a few variables is problematic, with risk
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estimates that vary widely between studies. The most
logical response is to develop a multivariate model
from a large dataset, and to validate it in a separate
cohort of patients. Van Zee et al.7 have done so,
drawing on our own experience in 1,075 SLN-positive
patients who had a completion ALND. Multivariate
logistic regression was used in 702 patients to develop
a multivariate nomogram, the Memorial Sloan–Ket-
tering Cancer Center (MSKCC) nomogram. The
eight variables include tumor size, type/grade, LVI,
multifocality, estrogen receptor (ER) status, method
of SLN metastasis detection, number of SLN posi-
tive, and number of SLN negative. This model was
validated prospectively in another 373 patients, and
in a calibration plot there was good agreement across
a wide range of probabilities between the predicted
and the observed rates of non-SLN metastasis. The
MSKCC nomogram (along with a more recent
nomogram for the prediction of SLN metastasis8) is
available online (www.mskcc.org/nomograms) in the
form of a simple calculator.
VALIDATING THE MSKCC NOMOGRAM
The MSKCC nomogram is simply a test to predict
the probability of non-SLN metastasis. The most
direct validation is to compare the predicted and
observed rates of non-SLN metastasis; in our own
calibration plots, the nomogram performs well across
a broad range of predicted rates.7 A more compre-
hensive measure of its performance is the receiver
operating characteristic (ROC) curve. ROC curves
were developed in World War II as part of a ﬁeld
called signal detection theory, and were used to
evaluate the ability of radar operators to distinguish
between the signals of enemy and friendly ships. They
are now widely used in medicine to assess test per-
formance; we recommend a particularly lucid online
discussion of this topic by Tape.9
The ROC curve plots true positives (sensitivity) on
the Y axis against false positives (1 - speciﬁcity) on
the X axis (Fig. 1). A test’s accuracy (ability to dis-
tinguish between patients with and without a condi-
tion) is represented by the area under the curve
(AUC). An AUC of 1 (a vertical line along the Y axis)
indicates a perfect test with no false-positive results;
an AUC of 0.5 (a diagonal line at 45) indicates a
worthless test with an equal number of true-positive
and false-positive results, the equivalent of a coin
toss.
Most diagnostic tests, including our nomogram,
are imperfect and have an AUC somewhere in be-
tween. The MSKCC nomogram AUC of 0.77 means
that, between two randomly selected SLN-positive
patients of whom one has a positive non-SLN, the
nomogram would correctly identify that patient 77%
of the time. The MSKCC nomogram has been vali-
dated by 15 studies worldwide (Table 1),7,10–22
including that of Poirier et al.22 in this issue of the
Annals of Surgical Oncology, and other validation
series are certain to follow. The nomogram had
proved robust despite diﬀerences in patient demo-
graphics, clinical characteristics, surgical technique,
and pathologic processing. The AUC values range
from 0.58 to 0.86 and as one might expect, the highest
(0.82 and 0.86) and lowest (0.58) values come from
studies with fewer than 100 patients.
CRITIQUING THE NOMOGRAM:
CAN WE DO BETTER?
Nomogram development lends itself to statistical
tweaking, and many groups have raised caveats and
proposed improved models. Degnim et al.11 selected
subsets of their patients in whom the MSKCC
nomogram predicted £5% and £10% probabilities of
non-SLN metastases, and observed false-negative
rates of 17% and 11%, respectively; using a modiﬁed
model, they were able to reduce the false-negative
FIG. 1. A comparison of ROC curves for excellent, good, and
worthless diagnostic tests. In a worthless test (AUC = 0.50), there
are equal numbers of true-positive and false-positive results;
adapted from Tape.9
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rate for low-risk patients, but without increasing the
AUC. Alran et al.17 observed an AUC of 0.72 for all
of their patients, but only 0.52 for patients with SLN
micrometastases (£2 mm), and concluded that the
nomogram was not reliable in low-probability cases.
Kohrt et al.,21 using three different statistical tech-
niques, developed a model based on three variables
(tumor size, LVI, and SLN metastasis size) which
outperformed the MSKCC nomogram in their own
patients, with AUCs of 0.83–0.85 versus 0.77. Of
note, only 60% of their 285 patients had complete
pathologic data. Coutant et al.23 reported a scoring
system based on three variables (tumor size, presence/
absence of macrometastasis, and no. of positive SLNs
divided by no. of SLNs removed), and achieved an
AUC of 0.82. Pal et al.19 added SLN metastasis size
to their model and improved the AUC from 0.68
(MSKCC) to 0.84. Finally, Dauphine et al.13 (in 39
patients) applied three different scoring systems, ob-
served AUCs of 0.63, 0.70, and 0.68, and advised
caution in the application of each.
It is worth emphasizing that subset analyses of
nomogram performance are problematic. Alran
et al.17 observed a poor AUC (0.52) for patients with
SLN micrometastases, but their own unpublished
data (S. Alran, personal communication) indicate
good agreement between the observed and predicted
rates of non-SLN involvement for patients with SLN
micrometastases £2 mm (14% observed versus 10%
predicted) and for patients with SLN positive only on
IHC (11% observed versus 9% predicted). In this
issue of the Annals of Surgical Oncology, Poirier
et al.22 report that, for their patients with nomogram
scores of £10% (18% of all cases), the observed rate
of non-SLN metastasis was 13% [95% conﬁdence
interval (CI) 2–24%]. Based on a small sample size
(n = 37) with wide conﬁdence intervals, this degree
of variation is not at all surprising. Taken together,
these studies demonstrate that: (1) a low AUC in a
small subset indicates lack of precision in being able
to discriminate between two numbers within a small
range (for example 11% versus 9%), a deﬁciency
which is not clinically relevant, and (2) an observed
rate of non-SLN metastasis lower or higher than the
predicted value neither proves nor disproves the value
of the nomogram. In fact, the nomogram performed
well in both studies.
There is to date no standardized methodology for
pathologic analysis of SLN, and this inconsistency
may account for at least some of the observed vari-
ation in nomogram performance. We began to per-
form SLN biopsy in 1996, adopted a pathologic
protocol using serial sections/IHC,24 and, in the
MSKCC nomogram, categorized SLN metastasis by
pathologic detection (frozen section, routine H&E,
serial sections, IHC-only). Current American Joint
Committee on Cancer (AJCC) staging25 categorizes
nodal metastases on the basis of size (£0.2 mm, 0.2–
2 mm,>2 mm) and we are now updating the nomo-
gram on this basis. We agree with Turner et al.26 that
AJCC lymph-node staging is subject to wide inter-
pretive variation, and that there is substantial room
for improvement. Lymph node staging should be
simple, reproducible, cost effective, and clinically
relevant; in current practice, we have not yet achieved
these goals.
THE NOMOGRAM IN EVERYDAY PRACTICE:
WHAT IT CAN AND CANNOT DO
First, the MSKCC nomogram was designed to
estimate the probability of non-SLN metastases in
SLN-positive patients, not to determine with certainty
that non-SLN disease is (or is not) present. It is
crucial to recognize that the nomogram correctly
discriminates between randomly selected patients
with and without SLN metastases in about three-
quarters of cases, i.e., that it is not perfect.
Second, the MSKCC nomogram is superior to
clinical judgment. In two separate studies using
hypothetical scenarios,27,28 the nomogram outper-
formed clinician ‘‘guesstimates’’ (in one of these,27 the
AUC values for nomogram versus clinicians were 0.72
versus 0.54, P< 0.01). It is again crucial to recognize
that the nomogram is a more accurate guess than
clinical judgment, but that it remains a guess.
TABLE 1. Results of series validating the MSKCC nomo-
gram
Reference Patients (n) AUC
Van Zee et al. (2003)7 373 0.77
Smidt et al. (2005)10 222 0.78
Degnim et al. (2005, Mayo)11 465 0.72
Degnim et al. (2005, Michigan)11 89 0.86
Soni et al. (2005)12 149 0.75
Dauphine et al. (2007)13 51 0.63
Cripe et al. (2006)14 92 0.82
Lambert et al. (2006)15 200 0.71
Zgajnar et al. (2007)16 276 0.72
Alran et al. (2007)17 588 0.72
Cserni (2007)18 140 0.73
Pal et al. (2008)19 118 0.68
Klar et al. (2008)20 98 0.58
Kohrt et al. (2008)21 171 0.77
Poirier et al. (2008)22 209 0.69
MSKCC, Memorial Sloan–Kettering Cancer Center; AUC, area
under the ROC curve.
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Third, the MSKCC nomogram cannot tell us (or
our patients) what to do; there is no cutoff nomogram
score which mandates the performance of an ALND.
When Poirier et al.22 in this issue of the Annals of
Surgical Oncology state that 71% of Quebec surgeons
would not perform an ALND for nomogram scores
of £10%, they imply a 10% cutoﬀ. While we have
observed a declining rate of ALND in our SLN-po-
sitive patients and lower nomogram scores in SLN-
positive patients who did not have ALND compared
with those who did (10% versus 37%), the range in
nomogram scores for the no-ALND patients was
wide (1–89).29 The decision for ALND in SLN-posi-
tive patients should be individualized considering
multiple factors (patient age, comorbidities, anxiety
level, and implications for systemic therapy, among
others), and not based on the nomogram score alone.
FUTURE DIRECTIONS: ARE WE ASKING
THE WRONG QUESTION?
At present, the most important reasons for ALND
in SLN-positive patients are to guide systemic therapy
and to prevent local recurrence. The decision for sys-
temic therapy is multifactorial, and, for SLN-positive
patients, is infrequently changed by the discovery of
additional positive nodes. For the occasional SLN-
positive patient in whom systemic therapy might be
changed, completion ALND is reasonable. In our
opinion, this assessment is better made by the medical
oncologist than the surgeon.
Regarding local control, six series (n = 583, 2003–
2007) of selected SLN-positive/no-ALND patients
report axillary local recurrence (LR) of 0.5% at a
median follow-up of 31 months, results quite com-
parable to those in 14 series (n = 3802, 2004–2007)
of SLN-negative/no-ALND patients: 0.3% at
47 months’ follow-up.30 In our own series of SLN-
positive/no-ALND patients,29 we observed axillary
LR as a ﬁrst event in 1% (3 of 287 patients) at follow-
up of 23 months. It seems inconceivable that these
very low rates of axillary LR would ever reach 10%,
the level at which LR had a detectable adverse effect
on survival in the most recent Early Breast Cancer
Trialists’ Collaborative Group overview.31 Across the
burgeoning literature validating the MSKCC nomo-
gram, we are in effect asking the question, ‘‘Which
SLN-positive patients do not need ALND?’’ It is quite
clear from the data above that at least some do not
and that practice patterns are changing. The Ameri-
can College of Surgeons Oncology Group (ACO-
SOG) Z0011 trial32 (a randomization of SLN-positive
patients to ALND versus observation) closed early
due to slow accrual and low event rates, but was
ahead of its time in asking a better question: ‘‘Which
SLN-positive patients, if any, need ALND?’’ It is
time to ask this question again.
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